Dingdang Health Technology Group (9886) H2 2023 earnings summary

Executive summary

• FY2023 revenue rose 12.2% YoY to RMB4,856.8m; net loss narrowed 91.9% to RMB230.9m, while adjusted net loss narrowed 17.2% to RMB106.6m.

• Growth reflected a larger user base, more sales orders and broader product categories; cost reduction and efficiency improvements supported lower losses.

Financial highlights

• Gross profit increased to RMB1,510.7m from RMB1,449.7m, but gross margin declined to 31.1% from 33.5%, mainly due to product sales mix.

• Net loss was RMB230.9m versus RMB2,842.3m; loss attributable to owners was RMB225.8m versus RMB2,833.4m.

• Adjusted net loss, excluding fair value losses on preferred-right liabilities, share-based payments and listing expenses, was RMB106.6m versus RMB128.7m.

• Basic and diluted loss per share improved to RMB0.17 from RMB3.37.

Outlook and guidance

• 2024 priorities include expanding core-city service density, entering new cities, deepening industry partnerships and developing an integrated Treatment, Diagnosis, Pharmaceutical Products and Medical Insurance ecosystem.

• Planned areas include AI-enabled medical services, online medical insurance payment, cold-chain delivery, new categories and an all-channel sales system; no numerical earnings guidance was stated.